Last reviewed 2026-05-14 · How we verify

First placebo, than Tranexamic acid.

Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing bleeding.

Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing bleeding. Used for Reduction of blood loss in surgical procedures, Management of bleeding in hemophilia and other bleeding disorders.

At a glance

Mechanism of action

Tranexamic acid is a competitive inhibitor of plasminogen and plasmin, which are key enzymes in the fibrinolytic cascade responsible for breaking down blood clots. By inhibiting these enzymes, tranexamic acid stabilizes fibrin clots and reduces excessive bleeding. It is commonly used to reduce blood loss in surgical procedures and manage bleeding disorders.

Approved indications

• Reduction of blood loss in surgical procedures
• Management of bleeding in hemophilia and other bleeding disorders

Common side effects

• Thromboembolic events
• Nausea
• Diarrhea
• Headache

Key clinical trials

• Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery (EARLY_PHASE1)
• Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis (PHASE3)
• Reduction Bleeding in Laminectomy With Double Doses of Tranexamic Acid (PHASE4)
• Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• First placebo, than Tranexamic acid. CI brief — competitive landscape report
• First placebo, than Tranexamic acid. updates RSS · CI watch RSS
• University Hospital, Saarland portfolio CI